TP53 and B-cell chronic lymphocytic leukemia: Moreover, since BIRC3 disruption in CLL patients has been associated with fludarabine refractoriness even in TP53 wild-type CLLs [10], we tested HG3-del(11q) clones (with or without BIRC3 disruption) for evidence of resistance to fludarabine treatment.